Crowley Wealth Management Inc. Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

Crowley Wealth Management Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel.com reports. The firm acquired 2,151 shares of the biopharmaceutical company’s stock, valued at approximately $57,000.

A number of other institutional investors have also made changes to their positions in the stock. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer in the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

Pfizer stock opened at $26.20 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $148.61 billion, a P/E ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. The business’s fifty day moving average is $26.17 and its two-hundred day moving average is $27.04. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.